The model was developed from a registry of 924 adult patients with locally advanced, unresectable or metastatic distal esophageal, GEJ, or gastric cancer treated between 2008 and 2014 at 28 Spanish teaching hospitals. It was subsequently validated in a prospective sample comprising 384 patients treated between 2014 and 2016. The registry’s basic eligibility criteria included patients who were fit enough to receive conventional first line polychemotherapy validated in phase III studies, regardless of management taking place within the context of normal healthcare or in a clinical trial. To derive the nomogram, we considered 29 routinely available, baseline clinical-pathological variables attained before the start of first-line chemotherapy.

The scope of the model’s applicability must always be confirmed and attention must be paid to unusual risk factors that may be important in a minority of patients, as well as those that might eventually develop during the course of the disease, since only baseline variables have been contemplated.

Predictions are merely approximate, so decisions should be taken at the discretion of the attending physician.

Disclaimer: This tool is intended for use by healthcare professionals only. Patients with advanced gastric cancer should seek medical care. Physicians and other healthcare professionals who use the AGAMENON calculator should exercise their own clinical judgment. This app does not provide professional advice. We have exercised great caution in creating this app, based on real-world data. However, medical standards and practice may vary as new information becomes available and professionals should consult a variety of medical sources. While we estimate survival probability for advanced gastric cancer patients undergoing first-line chemotherapy, we in no way endorse any particular management strategy. Your reliance upon predictions obtained through this app is solely at your own risk. We assume no liability or responsibility whatsoever for damage or injury (including death) to you or anyone else from the use of this tool.


  1. A Custodio, A Carmona-Bayonas, P Jiménez-Fonseca, M L Sánchez, A Viudez, R Hernández, J M Cano, I Echavarria, C Pericay, M Mangas, L Visa, E Buxo, T García, A Rodríguez Palomo, F Álvarez Manceñido, A Lacalle, I Macias, A Azkarate, A Ramchandani, A Fernández Montes, C López, F Longo, R Sánchez Bayona, M L Limón, A Díaz-Serrano, A Hurtado, R Madero, C Gómez and J Gallego on behalf of the AGAMENON study group (2017). Nomogram-based prediction of survival in patients with advanced oesophagogastric adenocarcinoma receiving first-line chemotherapy: a multicenter prospective study in the era of trastuzumab. British Journal of Cancer, 116(12), 1526-1535.
  2. Download